Importantly, the combined therapy enhanced the population of CD3 + T cells, CD8 + T cells, IFN-γ + CD8 + T cells, and TNF-α + CD8 + T cells markedly in the tumor region (Fig. 6h, i). The gene discussed is CD8A; the disease is neoplasm.